Superlab Far East Limited
Records under this name other than the patents Superlab Far East Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
Showing 1 to 7 of 7 · Back to Superlab Far East Limited
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,585,647 | Nucleic acid encoding recombinant interferon Term ended Term ended Jul 1, 2025 · USPTO record | Term ended | Term ended Jul 1, 2025 | USPTO record |
| US 8,287,852 | Treatment of viral diseases with recombinant interferon α Term ended Ended no later than Aug 26, 2024 · USPTO record | Term ended | Ended no later than Aug 26, 2024 | USPTO record |
| US 9,944,686 | Treatment of tumors with recombinant interferon alpha Term ended Term ended Jun 1, 2023 · USPTO record | Term ended | Term ended Jun 1, 2023 | USPTO record |
| US 8,114,395 | Treatment of viral diseases with recombinant interferon α Term ended Term ended Apr 2, 2022 · USPTO record | Term ended | Term ended Apr 2, 2022 | USPTO record |
| US 7,364,724 | Recombinant super-compound interferon Term ended Term ended Feb 28, 2022 · USPTO record | Term ended | Term ended Feb 28, 2022 | USPTO record |
| US 8,425,896 | Treatment of tumors with recombinant interferon alpha Term ended Ended no later than Feb 28, 2022 · USPTO record | Term ended | Ended no later than Feb 28, 2022 | USPTO record |
| US 8,551,469 | Treatment of tumors and viral diseases with recombinant interferon alpha Term ended Ended no later than Feb 28, 2022 · USPTO record | Term ended | Ended no later than Feb 28, 2022 | USPTO record |